Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +16.10%
#2 Fake World Assets Fake World Assets +11.89%
#3 OriginTrail OriginTrail +8.84%
#4 B3 (Base) B3 (Base) +7.77%
#5 Pons Pons +5.38%
#6 Storj Storj +5.13%
#7 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +4.30%
#8 Audiera Audiera +3.81%
#9 Strategy PP Variable xStock Strategy PP Variable xStock +3.03%
#10 Geodnet Geodnet +2.92%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGM
Classement en actions #20909
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering... NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
Prix de l'action
$1.54
Dernière synchronisation: 2024-04-08
Capitalisation boursière
$119.21M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange NGM Biopharmaceuticals, Inc. (NGM)

Catégorie

Healthcare
Bénéfices pour NGM Biopharmaceuticals, Inc. (NGM)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de NGM Biopharmaceuticals, Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour NGM Biopharmaceuticals, Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH